Lv52
934 积分 2026-03-02 加入
Fifth edition WHO classification: myeloid neoplasms
1个月前
已完结
Venetoclax plus decitabine, cytarabine, aclarubicin, and G‐ CSF in adults with newly diagnosed acute myeloid leukemia: A multicenter, retrospective study
4个月前
已完结
The BCL-2–tumor microenvironment axis: Mechanisms of immune suppression, resistance, and pathways to therapeutic reprogramming
4个月前
已完结
Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome
4个月前
已完结
Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis
4个月前
已完结
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
4个月前
已完结
Clinical Pharmacology of Brain Tumor Chemotherapy
4个月前
已完结
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML
4个月前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
4个月前
已完结
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
5个月前
已完结
皖公网安备34019202002308
